sotalol has been researched along with Tachycardia, Supraventricular in 77 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Tachycardia, Supraventricular: A generic expression for any tachycardia that originates above the BUNDLE OF HIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a randomized, double-blind, placebo-controled, parallel-group comparison study of the efficacy and safety of sotalol in the prophylaxis of paroxysmal supraventricular tachyarrhythmias (PSVTs) (including paroxysmal atrial fibrillation and paroxysmal reentrant SVTs)." | 9.08 | Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. ( Anderson, K; Joseph, SP; Joy, M; Wanless, RS, 1997) |
| "We sought to determine the yield of in-hospital monitoring for detection of significant arrhythmia complications in patients starting sotalol therapy for atrial arrhythmias and to identify factors that might predict safe outpatient initiation." | 7.70 | Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. ( Chung, MK; Jaeger, FJ; Kidwell, GA; Miller, DP; Morant, VA; Niebauer, MJ; Pinski, SL; Schweikert, RA; Tchou, PJ; Trohman, RG; Wilkoff, BL, 1998) |
| "Sotalol is an antiarrhythmic agent with combined beta-blocking and class III antiarrhythmic properties." | 6.68 | Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. ( Das, G; Falk, R; Hanyok, JJ; Hardy, SA; Karagounis, L; Platia, E; Sung, RJ; Tan, HL, 1995) |
| "The incidence of supraventricular arrhythmias was not significantly different in the two groups (3/19 in the sotalol group, 5/17 in the control group)." | 6.67 | Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery. ( Dion, R; Evenepoel, M; Evrard, P; Goenen, M; Jacquet, L; Marenne, F; Verhelst, R, 1994) |
| "Sotalol was developed as a nonselective beta-blocker in the 1960s for the treatment of hypertension and later for cardiac risk management after myocardial infarction." | 6.39 | Sotalol: a new agent for the treatment of ventricular arrhythmias. ( Grubb, BP; Samoil, D; Temesy-Armos, PN, 1994) |
| "We performed a randomized, double-blind, placebo-controled, parallel-group comparison study of the efficacy and safety of sotalol in the prophylaxis of paroxysmal supraventricular tachyarrhythmias (PSVTs) (including paroxysmal atrial fibrillation and paroxysmal reentrant SVTs)." | 5.08 | Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. ( Anderson, K; Joseph, SP; Joy, M; Wanless, RS, 1997) |
| " In the case of atrial flutters the pregnant woman is treated with sotalol administered orally and, if no sinus rhythm is obtained nor a reduced ventricular rhythm occurs, subsequently with digoxin." | 4.81 | [Protocols for the treatment of supraventricular tachycardias in the fetus]. ( Ambachtsheer, EB; Meijboom, EJ; Oudijk, MA; Stoutenbeek, P, 2001) |
| "Racemic sotalol is an effective Class III antiarrhythmic agent approved by the Food and Drug Administration for the treatment of documented life-threatening ventricular arrhythmias." | 4.78 | Sotalol: a breakthrough antiarrhythmic? ( McCollam, PL; Nappi, JM, 1993) |
| " Arrhythmias for which sotalol was initiated included atrioventricular reciprocating tachycardia/atrioventricular nodal reciprocating tachycardia (n = 105 [55%]), atrial flutter (n = 31 [16%]), ectopic atrial tachycardia (n = 26 [14%]), VT (n = 21 [11%]), and atrial fibrillation (n = 7 [4%])." | 3.96 | Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population. ( Abrams, DJ; Alexander, ME; Bevilacqua, LM; Bezzerides, VJ; Chandler, SF; Chu, E; DeWitt, ES; Mah, DY; Triedman, JK; Walsh, EP; Whitehill, RD, 2020) |
| "We sought to determine the yield of in-hospital monitoring for detection of significant arrhythmia complications in patients starting sotalol therapy for atrial arrhythmias and to identify factors that might predict safe outpatient initiation." | 3.70 | Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. ( Chung, MK; Jaeger, FJ; Kidwell, GA; Miller, DP; Morant, VA; Niebauer, MJ; Pinski, SL; Schweikert, RA; Tchou, PJ; Trohman, RG; Wilkoff, BL, 1998) |
| "Standardized treatment of fetal tachyarrhythmia has not been established." | 2.90 | Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial. ( Hagiwara, A; Hamasaki, T; Horigome, H; Ikeda, T; Inamura, N; Kato, H; Katsuragi, S; Kawataki, M; Maeno, Y; Miyoshi, T; Nii, M; Sago, H; Sakaguchi, H; Shimizu, W; Shiraishi, I; Taketazu, M; Ueda, K; Yamamoto, H; Yasukochi, S; Yoda, H, 2019) |
| "To derive useful pharmacokinetic (PK) and pharmacodynamic (PD) information for guiding the clinical use of sotalol in pediatric patients with supraventricular (SVT) or ventricular tachyarrhythmia (VT)." | 2.70 | Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. ( Gastonguay, MR; Hinderling, PH; Ludden, TM; Melikian, AP; Shi, J, 2001) |
| " The dosing interval was 8 hours." | 2.70 | Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia. ( Barbey, JT; Beerman, L; Hinderling, PH; Jin, J; Melikian, AP; Ross, B; Saul, JP; Schaffer, MS; Shi, J; Williams, J, 2001) |
| " The elimination of sotalol was characterized by an average half-life of between 7." | 2.70 | Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia. ( Cai, B; Epstein, MR; Erickson, CC; Hinderling, PH; Karara, AH; Karpawich, PP; Melikian, AP; Saul, JP; Schaffer, MS; Shi, J, 2001) |
| "Sotalol is an antiarrhythmic agent with combined beta-blocking and class III antiarrhythmic properties." | 2.68 | Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. ( Das, G; Falk, R; Hanyok, JJ; Hardy, SA; Karagounis, L; Platia, E; Sung, RJ; Tan, HL, 1995) |
| " A total of 15 possible adverse effects were reported, occurring in 10 patients with sotalol versus 4 with placebo." | 2.67 | Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. The Sotalol Versus Placebo Multicenter Study Group. ( Gorgels, A; Jordaens, L; Stroobandt, R; Temmerman, J, 1991) |
| "The incidence of supraventricular arrhythmias was not significantly different in the two groups (3/19 in the sotalol group, 5/17 in the control group)." | 2.67 | Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery. ( Dion, R; Evenepoel, M; Evrard, P; Goenen, M; Jacquet, L; Marenne, F; Verhelst, R, 1994) |
| " Drug-related adverse effects necessitating discontinuation of the drug occurred in four receiving low doses (2." | 2.67 | Efficacy and safety of low- and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations. ( Adan, AJ; Defauw, JA; Ernst, SM; Kingma, JH; Koomen, EM; Suttorp, MJ; Tjon Joe Gin, RM; van Hemel, NM, 1990) |
| "Sotalol was approved for treatment of atrial fibrillation and atrial flutter (AF)." | 2.42 | Oral class III antiarrhythmics: what is new? ( Khan, MH, 2004) |
| "Sotalol was developed as a nonselective beta-blocker in the 1960s for the treatment of hypertension and later for cardiac risk management after myocardial infarction." | 2.39 | Sotalol: a new agent for the treatment of ventricular arrhythmias. ( Grubb, BP; Samoil, D; Temesy-Armos, PN, 1994) |
| "Sotalol is a novel antiarrhythmic agent combining beta-adrenergic-antagonist actions with the ability to increase cardiac repolarization and refractoriness." | 2.39 | Sotalol. ( Hohnloser, SH; Woosley, RL, 1994) |
| "Successful arrhythmia termination occurred in 31 patients (49%, 95% CI [37%-62%]) with improvement in rhythm control defined as rate reduction permitting overdrive pacing in an additional 18 patients (30%, 95% CI [19%-41%])." | 1.72 | IV Sotalol Use in Pediatric and Congenital Heart Patients: A Multicenter Registry Study. ( Asaki, SY; Avari Silva, JN; Balaji, S; Chang, PM; Fischbach, PS; Garnreiter, JM; Kirk, C; Malloy-Walton, LE; Moak, JP; Nguyen, HH; Ochoa, LA; Patel, AR; Saul, JP; Sherman, AK; Von Bergen, NH, 2022) |
| "Fetal arrhythmias are common, and they may resolve spontaneously in majority of the cases." | 1.56 | Fetal arrhythmias: diagnosis and treatment. ( Yuan, SM, 2020) |
| "Fetal hydrops was present in six patients (five with SVT, one with AF)." | 1.39 | Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up. ( Freund, MW; Manten, GT; Oudijk, MA; Pistorius, L; ter Heide, H; van der Heijden, LB, 2013) |
| "Adenosine has been well studied as a mainstay treatment, but the methods of adenosine administration have not been very well delineated." | 1.38 | Intraosseous infusion is unreliable for adenosine delivery in the treatment of supraventricular tachycardia. ( Goodman, IS; Lu, CJ, 2012) |
| "Sotalol was associated with higher rates of prenatal AF termination than digoxin (HR=5." | 1.37 | Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. ( Api, O; Blom, NA; Carvalho, JS; Clur, SA; De Groot, E; Jaeggi, ET; Manlhiot, C; McCrindle, BW; Rammeloo, L; Ryan, G, 2011) |
| " Age-factor nomogram dosing of sotalol is widely used; however, our institution uses greater doses based on body surface area (approximately 150-200 mg/m(2)/d)." | 1.37 | High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias. ( Cannon, BC; Kim, JJ; Knudson, JD; Moffett, BS, 2011) |
| "Digoxin therapy was initiated and sotalol was later added for new-onset hydrops." | 1.35 | Can digoxin and sotalol therapy for fetal supraventricular tachycardia and hydrops be successful? A case report. ( Gonzalez, JM; Merriman, JB; Rychik, J; Ural, SH, 2008) |
| "A rapid onset of an effective and safe antiarrhythmic sotalol therapy, especially for infants and neonates, is frequently delayed because of age-dependent interpatient variability in pharmacokinetics and pharmacodynamics." | 1.33 | Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. ( Elshoff, JP; Hulpke-Wette, M; Läer, S; Meibohm, B; Mir, TS; Weil, J; Zhang, W, 2005) |
| "Supraventricular tachycardia is the most common clinically significant fetal tachycardia." | 1.32 | Fetal supraventricular tachycardia diagnosed and treated at twenty-four weeks of gestation and after birth: a case report. ( Annunziata, A; Calabrò, R; Cardaropoli, D; D'Alto, M; Pacileo, G; Paladini, D; Romeo, E; Russo, MG; Sarubbi, B, 2004) |
| "Hydrops fetalis was present in 9 fetuses." | 1.31 | Sotalol in the treatment of fetal dysrhythmias. ( Kapusta, L; Kleinman, CS; Meijboom, EJ; Michon, MM; Oudijk, MA; Stoutenbeek, P; Visser, GH, 2000) |
| "Sotalol was given orally to the mothers in a dose of 80-160 mg x 2." | 1.30 | Foetal supraventricular tachycardia treated with sotalol. ( Fouron, JC; Jaeggi, E; Sonesson, SE; Wesslen-Eriksson, E; Winberg, P, 1998) |
| "Dl-sotalol was first choice medication in only three patients." | 1.29 | [Experience with dl-sotalol in the treatment of supraventricular arrhythmia]. ( Adragão, P; Almeida, M; Bonhorst, D; Caires, G; Mesquita, A; Morgado, F; Parreira, L; Seabra-Gomes, R; Trabulo, M, 1996) |
| "Sotalol was administered to 32 patients with a mean age of 8." | 1.29 | [Results of oral sotalol therapy in children with supraventricular and ventricular arrhythmias]. ( Kallfelz, HC; Lehmann, C; Paul, T; Pfammatter, JP, 1994) |
| "Sotalol was discontinued most commonly for either spontaneous resolution of disease or definitive cure by radiofrequency ablation." | 1.29 | Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome. ( Lulu, JA; Saul, JP; Tanel, RE; Walsh, EP, 1995) |
| "Sotalol is an effective, safe drug for the treatment of supraventricular tachycardias in early infancy." | 1.28 | Efficacy and safety of oral sotalol in early infancy. ( Sandor, G; Tipple, M, 1991) |
| "Sotalol has a virtually unique antiarrhythmic profile in that it combines the properties of the Class II beta-blocking agents with the Class III properties that prolong repolarization." | 1.28 | Mechanism of action of sotalol in supraventricular arrhythmias. ( Brugada, J; Brugada, P; Farré, J; Smeets, JL, 1990) |
| "Amiodarone was administered intravenously at a dose of 300 mg over 2 min and sotalol at a dose of 1." | 1.28 | Mechanisms of termination of supraventricular tachycardias by intravenous class III antiarrhythmic agents. A comparison of amiodarone and sotalol. ( Dehareng, A; Kulbertus, HE; Nzayinambaho, K; Rodriguez, LM; Waleffe, A, 1989) |
| "2% after intravenous d-sotalol, but no adverse symptoms developed." | 1.28 | Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias. ( Bigger, JT; Kidwell, GA; Reiffel, JA; Sahar, DI; Squatrito, A, 1989) |
| "Sotalol was well tolerated in 21 patients; one patient complained of cold in the legs and one patient developed asymptomatic bradycardia (46 bpm)." | 1.27 | [Intravenous sotalol in the acute treatment of supraventricular tachycardias]. ( Bru, P; Cointe, R; Gérard, R; Lévy, S; Metge, M; Nassi, C; Rovini, JC, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (9.09) | 18.7374 |
| 1990's | 34 (44.16) | 18.2507 |
| 2000's | 16 (20.78) | 29.6817 |
| 2010's | 12 (15.58) | 24.3611 |
| 2020's | 8 (10.39) | 2.80 |
| Authors | Studies |
|---|---|
| Valdés, SO | 1 |
| Howard, TS | 1 |
| Pham, TDN | 1 |
| Lemming, KI | 1 |
| Rochelson, E | 1 |
| Backes, ER | 1 |
| Lam, WW | 1 |
| Patel, R | 1 |
| Miyake, CY | 1 |
| Kim, JJ | 2 |
| Malloy-Walton, LE | 1 |
| Von Bergen, NH | 1 |
| Balaji, S | 1 |
| Fischbach, PS | 1 |
| Garnreiter, JM | 1 |
| Asaki, SY | 2 |
| Moak, JP | 1 |
| Ochoa, LA | 1 |
| Chang, PM | 1 |
| Nguyen, HH | 1 |
| Patel, AR | 1 |
| Kirk, C | 1 |
| Sherman, AK | 1 |
| Avari Silva, JN | 1 |
| Saul, JP | 4 |
| Miyoshi, T | 2 |
| Maeno, Y | 2 |
| Hamasaki, T | 2 |
| Inamura, N | 2 |
| Yasukochi, S | 2 |
| Kawataki, M | 2 |
| Horigome, H | 2 |
| Yoda, H | 2 |
| Taketazu, M | 2 |
| Nii, M | 2 |
| Hagiwara, A | 2 |
| Kato, H | 2 |
| Shimizu, W | 2 |
| Shiraishi, I | 2 |
| Sakaguchi, H | 2 |
| Ueda, K | 2 |
| Katsuragi, S | 2 |
| Yamamoto, H | 2 |
| Sago, H | 2 |
| Ikeda, T | 2 |
| Refaat, M | 1 |
| El Dick, J | 1 |
| Sabra, M | 1 |
| Bitar, F | 1 |
| Tayeh, C | 1 |
| Abutaqa, M | 1 |
| Arabi, M | 1 |
| Chandler, SF | 1 |
| Chu, E | 1 |
| Whitehill, RD | 1 |
| Bevilacqua, LM | 1 |
| Bezzerides, VJ | 1 |
| DeWitt, ES | 1 |
| Alexander, ME | 1 |
| Abrams, DJ | 1 |
| Triedman, JK | 1 |
| Walsh, EP | 2 |
| Mah, DY | 1 |
| Etheridge, SP | 1 |
| Bjeloševič, M | 1 |
| Illíková, V | 1 |
| Tomko, J | 1 |
| Olejník, P | 1 |
| Chalupka, M | 1 |
| Hatala, R | 1 |
| Capponi, G | 1 |
| Belli, G | 1 |
| Giovannini, M | 1 |
| Remaschi, G | 1 |
| Brambilla, A | 1 |
| Vannuccini, F | 1 |
| Favilli, S | 1 |
| Porcedda, G | 1 |
| De Simone, L | 1 |
| Shozu, M | 1 |
| Bravo-Valenzuela, NJ | 1 |
| Peixoto, AB | 1 |
| Araujo Júnior, E | 1 |
| Tonni, G | 1 |
| Yuan, SM | 1 |
| Arsenault, KA | 1 |
| Yusuf, AM | 1 |
| Crystal, E | 1 |
| Healey, JS | 1 |
| Morillo, CA | 1 |
| Nair, GM | 1 |
| Whitlock, RP | 1 |
| Strasburger, JF | 1 |
| Ge, H | 1 |
| Li, X | 1 |
| Zhang, Y | 1 |
| Liu, H | 1 |
| Jiang, H | 1 |
| Merriman, JB | 1 |
| Gonzalez, JM | 1 |
| Rychik, J | 1 |
| Ural, SH | 1 |
| Ferasin, L | 1 |
| Mihálcz, A | 1 |
| Földesi, C | 1 |
| Kardos, A | 1 |
| Ladunga, K | 1 |
| Szili-Török, T | 1 |
| Suri, V | 1 |
| Keepanaseril, A | 1 |
| Aggarwal, N | 1 |
| Vijayvergiya, R | 1 |
| Knudson, JD | 1 |
| Cannon, BC | 1 |
| Moffett, BS | 1 |
| Kerin, NZ | 1 |
| Jacob, S | 1 |
| Jaeggi, ET | 1 |
| Carvalho, JS | 1 |
| De Groot, E | 1 |
| Api, O | 1 |
| Clur, SA | 1 |
| Rammeloo, L | 1 |
| McCrindle, BW | 1 |
| Ryan, G | 1 |
| Manlhiot, C | 1 |
| Blom, NA | 1 |
| Goodman, IS | 1 |
| Lu, CJ | 1 |
| Shah, A | 1 |
| Moon-Grady, A | 1 |
| Bhogal, N | 1 |
| Collins, KK | 1 |
| Tacy, T | 1 |
| Brook, M | 1 |
| Hornberger, LK | 1 |
| van der Heijden, LB | 1 |
| Oudijk, MA | 3 |
| Manten, GT | 1 |
| ter Heide, H | 1 |
| Pistorius, L | 1 |
| Freund, MW | 1 |
| Jouannic, JM | 1 |
| Delahaye, S | 1 |
| Le Bidois, J | 1 |
| Fermont, L | 1 |
| Villain, E | 1 |
| Dommergues, M | 1 |
| Dumez, Y | 1 |
| Khan, MH | 1 |
| Romeo, E | 1 |
| D'Alto, M | 1 |
| Russo, MG | 1 |
| Sarubbi, B | 1 |
| Cardaropoli, D | 1 |
| Paladini, D | 1 |
| Pacileo, G | 1 |
| Annunziata, A | 1 |
| Calabrò, R | 1 |
| DiDomenico, RJ | 1 |
| Massad, MG | 1 |
| Läer, S | 1 |
| Elshoff, JP | 1 |
| Meibohm, B | 1 |
| Weil, J | 1 |
| Mir, TS | 1 |
| Zhang, W | 1 |
| Hulpke-Wette, M | 1 |
| Paul, T | 1 |
| Lehmann, C | 1 |
| Pfammatter, JP | 1 |
| Kallfelz, HC | 1 |
| Tanel, RE | 1 |
| Lulu, JA | 1 |
| Bode-Böger, SM | 1 |
| Böger, RH | 1 |
| Frölich, JC | 1 |
| Hamer, AW | 1 |
| Strathmore, N | 1 |
| Vohra, JK | 1 |
| Hunt, VD | 1 |
| Sung, RJ | 1 |
| Tan, HL | 1 |
| Karagounis, L | 1 |
| Hanyok, JJ | 1 |
| Falk, R | 1 |
| Platia, E | 1 |
| Das, G | 1 |
| Hardy, SA | 1 |
| Daubert, C | 1 |
| Mabo, P | 1 |
| Gras, D | 1 |
| Leclercq, C | 1 |
| Jacquet, L | 1 |
| Evenepoel, M | 1 |
| Marenne, F | 1 |
| Evrard, P | 1 |
| Verhelst, R | 1 |
| Dion, R | 1 |
| Goenen, M | 1 |
| Gutiérrez-Larraya, F | 1 |
| Jabón, A | 1 |
| Hohnloser, SH | 1 |
| Woosley, RL | 1 |
| Dunnington, CS | 1 |
| Manz, M | 1 |
| Lüderitz, B | 1 |
| Pearce, SH | 1 |
| Rees, CJ | 1 |
| Smith, RH | 1 |
| Nappi, JM | 1 |
| McCollam, PL | 1 |
| Samoil, D | 1 |
| Grubb, BP | 1 |
| Temesy-Armos, PN | 1 |
| Leibowitz, D | 1 |
| Passaretti, B | 1 |
| Savasta, C | 1 |
| Sganzerla, P | 1 |
| Guazzi, MD | 1 |
| Trabulo, M | 1 |
| Almeida, M | 1 |
| Caires, G | 1 |
| Mesquita, A | 1 |
| Parreira, L | 1 |
| Morgado, F | 1 |
| Adragão, P | 1 |
| Bonhorst, D | 1 |
| Seabra-Gomes, R | 1 |
| Wanless, RS | 1 |
| Anderson, K | 1 |
| Joy, M | 1 |
| Joseph, SP | 1 |
| Pfisterer, ME | 1 |
| Klöter-Weber, UC | 1 |
| Huber, M | 1 |
| Osswald, S | 1 |
| Buser, PT | 1 |
| Skarvan, K | 1 |
| Stulz, PM | 1 |
| Tai, CT | 3 |
| Chen, SA | 3 |
| Chiang, CE | 1 |
| Lee, SH | 2 |
| Ueng, KC | 1 |
| Wen, ZC | 2 |
| Huang, JL | 1 |
| Chen, YJ | 1 |
| Yu, WC | 3 |
| Feng, AN | 3 |
| Chiou, CW | 1 |
| Chang, MS | 3 |
| Basta, M | 1 |
| Klein, GJ | 1 |
| Yee, R | 1 |
| Krahn, A | 1 |
| Lee, J | 1 |
| Kuo, BI | 1 |
| Ding, YA | 2 |
| Sonesson, SE | 1 |
| Fouron, JC | 1 |
| Wesslen-Eriksson, E | 1 |
| Jaeggi, E | 1 |
| Winberg, P | 1 |
| Chung, MK | 1 |
| Schweikert, RA | 1 |
| Wilkoff, BL | 1 |
| Niebauer, MJ | 1 |
| Pinski, SL | 1 |
| Trohman, RG | 1 |
| Kidwell, GA | 2 |
| Jaeger, FJ | 1 |
| Morant, VA | 1 |
| Miller, DP | 1 |
| Tchou, PJ | 1 |
| Marcus, FI | 1 |
| Michon, MM | 1 |
| Kleinman, CS | 1 |
| Kapusta, L | 1 |
| Stoutenbeek, P | 2 |
| Visser, GH | 1 |
| Meijboom, EJ | 2 |
| Schaffer, MS | 2 |
| Karpawich, PP | 1 |
| Erickson, CC | 1 |
| Epstein, MR | 1 |
| Melikian, AP | 3 |
| Shi, J | 3 |
| Karara, AH | 1 |
| Cai, B | 1 |
| Hinderling, PH | 3 |
| Ross, B | 1 |
| Beerman, L | 1 |
| Williams, J | 1 |
| Barbey, JT | 1 |
| Jin, J | 1 |
| Ambachtsheer, EB | 1 |
| Tahapary, GJ | 1 |
| Suttorp, MJ | 3 |
| Price, JF | 1 |
| Kertesz, NJ | 1 |
| Snyder, CS | 1 |
| Friedman, RA | 1 |
| Fenrich, AL | 1 |
| Ludden, TM | 1 |
| Gastonguay, MR | 1 |
| Inama, G | 1 |
| Furlanello, F | 1 |
| Vergara, G | 1 |
| Guarnerio, M | 1 |
| Braito, G | 1 |
| Nassivera, E | 1 |
| Tipple, M | 1 |
| Sandor, G | 1 |
| Huikuri, HV | 1 |
| Koistinen, MJ | 1 |
| Takkunen, JT | 1 |
| Kingma, JH | 2 |
| Peels, HO | 1 |
| Koomen, EM | 2 |
| Tijssen, JG | 1 |
| van Hemel, NM | 2 |
| Defauw, JA | 2 |
| Ernst, SM | 2 |
| Jordaens, L | 1 |
| Gorgels, A | 1 |
| Stroobandt, R | 1 |
| Temmerman, J | 1 |
| Tjon Joe Gin, RM | 1 |
| Adan, AJ | 1 |
| Brugada, P | 1 |
| Smeets, JL | 1 |
| Brugada, J | 1 |
| Farré, J | 1 |
| Camm, AJ | 1 |
| Paul, V | 1 |
| Waleffe, A | 1 |
| Nzayinambaho, K | 1 |
| Rodriguez, LM | 1 |
| Dehareng, A | 1 |
| Kulbertus, HE | 1 |
| Sahar, DI | 1 |
| Reiffel, JA | 1 |
| Bigger, JT | 1 |
| Squatrito, A | 1 |
| Lévy, S | 1 |
| Rovini, JC | 1 |
| Metge, M | 1 |
| Cointe, R | 1 |
| Bru, P | 1 |
| Nassi, C | 1 |
| Gérard, R | 1 |
| Bowman, E | 1 |
| Paes, BA | 1 |
| Way, RC | 1 |
| Gössinger, HD | 1 |
| Siostrzonek, P | 1 |
| Schmoliner, R | 1 |
| Grimm, G | 1 |
| Jäger, U | 1 |
| Mösslacher, H | 1 |
| Kunze, KP | 1 |
| Schlüter, M | 1 |
| Kuck, KH | 1 |
| Wehr, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Evaluation Analysis and Kinetics of IV Sotalol[NCT05247320] | 167 participants (Actual) | Observational | 2022-02-04 | Completed | |||
| A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery[NCT05780320] | 242 participants (Anticipated) | Observational | 2022-09-19 | Active, not recruiting | |||
| Pre-Operative Stellate Ganglion to Prevent Post-Operative Atrial Fibrillation[NCT05656170] | 0 participants (Actual) | Interventional | 2023-10-01 | Withdrawn (stopped due to Unable to begin study) | |||
| Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery[NCT05543278] | Phase 4 | 242 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement - a Randomized Controlled Trial[NCT05076019] | 266 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Post-Operative Atrial Fibrillation After Surgical Aortic Valve Replacement and the Influence of Statins - Randomized Controlled Trial[NCT05062239] | 100 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | |||
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| A Randomized Controlled Trial of Prophylactic Pulmonary Vein Isolation as Adjunct to Coronary Artery Bypass Grafting[NCT00338715] | Phase 3 | 193 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
18 reviews available for sotalol and Tachycardia, Supraventricular
| Article | Year |
|---|---|
Sotalol as an effective adjunct therapy in the management of supraventricular tachycardia induced fetal hydrops fetalis.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Female; Fetal Diseases; Flecainid | 2020 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery.
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac | 2013 |
Prenatal management with digoxin and sotalol combination for fetal supraventricular tachycardia: case report and review of literature.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Female; Humans; Hydrops Fetalis; | 2009 |
The efficacy of sotalol in preventing postoperative atrial fibrillation: a meta-analysis.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Drug Therapy, Combination; Electro | 2011 |
Oral class III antiarrhythmics: what is new?
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Phe | 2004 |
Pharmacologic strategies for prevention of atrial fibrillation after open heart surgery.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II; Anti-Arrhythmia Agents; Atrial Fibrillation | 2005 |
Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation.
Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Humans; | 1993 |
[Tachycardias: considerations in childhood in the 90s].
Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp | 1993 |
Sotalol.
Topics: Action Potentials; Animals; Electrocardiography; Electrophysiology; Humans; Myocardial Contraction; | 1994 |
Sotalol hydrochloride (Betapace): a new antiarrhythmic drug.
Topics: Adult; Angina Pectoris; Child; Clinical Protocols; Drug Interactions; Electrophysiology; Female; Hem | 1993 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Fle | 1993 |
Sotalol: a breakthrough antiarrhythmic?
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrophysiology; | 1993 |
Sotalol: a new agent for the treatment of ventricular arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Humans; Sotalol; Tachycardia, Supraventricular | 1994 |
Sotalol: a novel beta-blocker with class III anti-arrhythmic activity.
Topics: Arrhythmias, Cardiac; Heart Ventricles; Hemodynamics; Humans; Myocardial Ischemia; Sotalol; Tachycar | 1993 |
Current role of pharmacologic therapy for patients with paroxysmal supraventricular tachycardia.
Topics: Adenosine; Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Calcium Channel Blockers; Digoxin; El | 1997 |
Risks of initiating therapy with sotalol for treatment of atrial fibrillation.
Topics: Aged; Ambulatory Care; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flu | 1998 |
[Protocols for the treatment of supraventricular tachycardias in the fetus].
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Drug Therapy, Combination; Fema | 2001 |
Sotalol for paroxysmal supraventricular tachycardias.
Topics: Double-Blind Method; Humans; Randomized Controlled Trials as Topic; Sotalol; Tachycardia, Paroxysmal | 1990 |
15 trials available for sotalol and Tachycardia, Supraventricular
| Article | Year |
|---|---|
Antenatal Therapy for Fetal Supraventricular Tachyarrhythmias: Multicenter Trial.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Atrial Flutter; Cesarean Section; Digoxin; Fema | 2019 |
Oral flecainide, sotalol, and verapamil for the termination of paroxysmal supraventricular tachycardia.
Topics: Administration, Oral; Adult; Cardiac Pacing, Artificial; Female; Flecainide; Humans; Male; Middle Ag | 1993 |
Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Dose-Response Relationship, | 1995 |
Hemodynamic effects and safety of sotalol in the prevention of supraventricular arrhythmias after coronary artery bypass surgery.
Topics: Administration, Oral; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Cardia | 1994 |
Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; D | 1997 |
Prevention of supraventricular tachyarrhythmias after open heart operation by low-dose sotalol: a prospective, double-blind, randomized, placebo-controlled study.
Topics: Aged; Anti-Arrhythmia Agents; Aortic Valve; Coronary Artery Bypass; Double-Blind Method; Female; Hea | 1997 |
Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Electroph | 1998 |
Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia.
Topics: Adrenergic beta-Antagonists; Aging; Anti-Arrhythmia Agents; Child; Child, Preschool; Drug Administra | 2001 |
Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia.
Topics: Anti-Arrhythmia Agents; Area Under Curve; Child; Child, Preschool; Dose-Response Relationship, Drug; | 2001 |
Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia.
Topics: Anti-Arrhythmia Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; I | 2001 |
[Sotalol in the Wolff-Parkinson-White syndrome: an electrophysiological and clinical study].
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Electrocardiography; Electrophysiology; Fema | 1992 |
Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting.
Topics: Coronary Artery Bypass; Double-Blind Method; Female; Humans; Male; Middle Aged; Risk Factors; Sotalo | 1991 |
Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. The Sotalol Versus Placebo Multicenter Study Group.
Topics: Adult; Blood Pressure; Double-Blind Method; Female; Heart Rate; Humans; Injections, Intravenous; Mal | 1991 |
Efficacy and safety of low- and high-dose sotalol versus propranolol in the prevention of supraventricular tachyarrhythmias early after coronary artery bypass operations.
Topics: Administration, Oral; Coronary Artery Bypass; Female; Humans; Male; Middle Aged; Propranolol; Prospe | 1990 |
Sotalol for paroxysmal supraventricular tachycardias.
Topics: Double-Blind Method; Humans; Randomized Controlled Trials as Topic; Sotalol; Tachycardia, Paroxysmal | 1990 |
45 other studies available for sotalol and Tachycardia, Supraventricular
| Article | Year |
|---|---|
When adenosine is not enough.
Topics: Adenosine; Anti-Arrhythmia Agents; Humans; Sotalol; Tachycardia, Supraventricular | 2022 |
IV Sotalol Use in Pediatric and Congenital Heart Patients: A Multicenter Registry Study.
Topics: Arrhythmias, Cardiac; Child; Heart Defects, Congenital; Humans; Infant; Registries; Sotalol; Tachyca | 2022 |
Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Child, Preschool; Electrocardiography, Ambulatory; Fema | 2020 |
An Exciting New Tool in the Electrophysiologist's Toolbox, Intravenous Sotalol: Faster, Safer, Better?
Topics: Atrial Flutter; Humans; Sotalol; Tachycardia, Supraventricular | 2020 |
Supraventricular tachyarrhythmias during the intrauterine, neonatal, and infant period: A 10-year population-based study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Incidence; Infant; Infant, Newborn; Male; Pregna | 2020 |
Supraventricular tachycardias in the first year of life: what is the best pharmacological treatment? 24 years of experience in a single centre.
Topics: Action Potentials; Adrenergic beta-Antagonists; Age Factors; Anti-Arrhythmia Agents; Digoxin; Drug T | 2021 |
Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Child Development; Child, Preschool; Digoxin; Drug Therapy, | 2017 |
Fetal supraventricular tachycardia at 12 weeks of gestation: diagnosis and follow up. A case report.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Echocardiography; Female; Fetal Heart; Follow-Up Studies; Hu | 2019 |
Fetal arrhythmias: diagnosis and treatment.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Digoxin; Female; Humans; Hydrops Fetalis; Pregnancy; S | 2020 |
Re: Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up. L. B. van der Heijden, M. A. Oudijk, G. Manten, H. ter Heide, L. Pistorius and M. W. Freund. Ultrasound Obstet Gynecol 2013; 42: 285-293.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Female; Fetal Diseases; Humans; Pregnancy; Sotalol; Tachycar | 2013 |
[Clinical course and treatment of ectopic atrial tachycardia in 144 children].
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Catheter Ablation; Child; Child, Preschool; Ec | 2015 |
Can digoxin and sotalol therapy for fetal supraventricular tachycardia and hydrops be successful? A case report.
Topics: Adolescent; Anti-Arrhythmia Agents; Digoxin; Female; Fetal Therapies; Humans; Hydrops Fetalis; Pregn | 2008 |
Recurrent syncope associated with paroxysmal supraventricular tachycardia in a Devon Rex cat diagnosed by implantable loop recorder.
Topics: Animals; Anti-Arrhythmia Agents; Cat Diseases; Cats; Electrocardiography, Ambulatory; Male; Sotalol; | 2009 |
[Effectiveness of D,L-sotalol in post-ablative atrial arrhythmias in patients with atrial fibrillation treated with radiofrequency ablation].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Catheter | 2009 |
High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias.
Topics: Anti-Arrhythmia Agents; Child, Preschool; Dose-Response Relationship, Drug; Electrocardiography, Amb | 2011 |
Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study.
Topics: Anti-Arrhythmia Agents; Digoxin; Drug Evaluation; Female; Fetal Diseases; Fetal Therapies; Flecainid | 2011 |
Intraosseous infusion is unreliable for adenosine delivery in the treatment of supraventricular tachycardia.
Topics: Adenosine; Amiodarone; Catheterization, Central Venous; Combined Modality Therapy; Drug Therapy, Com | 2012 |
Effectiveness of sotalol as first-line therapy for fetal supraventricular tachyarrhythmias.
Topics: Abortion, Induced; Anti-Arrhythmia Agents; Atrial Flutter; Bradycardia; Catheter Ablation; Digoxin; | 2012 |
Sotalol as first-line treatment for fetal tachycardia and neonatal follow-up.
Topics: Anti-Arrhythmia Agents; Atrial Flutter; Echocardiography; Female; Fetal Diseases; Follow-Up Studies; | 2013 |
[Results of prenatal management of fetuses with supraventricular tachycardia. A series of 66 cases].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Flutter; Clinical Protocols; Digoxin; Echocardiography; F | 2003 |
Fetal supraventricular tachycardia diagnosed and treated at twenty-four weeks of gestation and after birth: a case report.
Topics: Adult; Anti-Arrhythmia Agents; Digoxin; Female; Fetal Distress; Flecainide; Gestational Age; Humans; | 2004 |
Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Infa | 2005 |
[Results of oral sotalol therapy in children with supraventricular and ventricular arrhythmias].
Topics: Administration, Oral; Adolescent; Adult; Atrial Flutter; Atrioventricular Node; Cardiac Complexes, P | 1994 |
Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Child; Child, Preschool; Female; Heart Conduction System; | 1995 |
[Comments on the contribution by Prof. Dr. S. H. Hohnloser. Sotalol].
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Metabolic Clearance Rate; So | 1995 |
Fetal monitoring during maternal antiarrhythmic therapy.
Topics: Adenosine; Adult; Atenolol; Cardiotocography; Drug Therapy, Combination; Female; Humans; Infant, New | 1993 |
Reversal of heart failure with sotalol in a case of incessant supraventricular tachycardia.
Topics: Adolescent; Anti-Arrhythmia Agents; Electrocardiography; Heart Failure; Humans; Male; Sotalol; Tachy | 1996 |
[Experience with dl-sotalol in the treatment of supraventricular arrhythmia].
Topics: Adult; Anti-Arrhythmia Agents; Female; Humans; Male; Middle Aged; Retrospective Studies; Sotalol; Ta | 1996 |
Characterization of low right atrial isthmus as the slow conduction zone and pharmacological target in typical atrial flutter.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Atrial Flutter; Cardiac Catheterization; Electrophy | 1997 |
Foetal supraventricular tachycardia treated with sotalol.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Female; Fetal Diseases; Gestational Age; Humans | 1998 |
Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia | 1998 |
Effects of procainamide and dl-sotalol on the changes of atrial electrophysiology induced by high current stimulation.
Topics: Adult; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Atrial Function; Atrial Premature Complex | 1998 |
Sotalol in the treatment of fetal dysrhythmias.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Follow-Up Studies; Humans; Hydrops Fetalis; Inf | 2000 |
Oral amiodarone and atrial fibrillation.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibril | 2001 |
Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age.
Topics: Anti-Arrhythmia Agents; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Therapy, Com | 2002 |
Efficacy and safety of oral sotalol in early infancy.
Topics: Digoxin; Drug Therapy, Combination; Electrocardiography; Female; Humans; Infant, Newborn; Male; Sota | 1991 |
Efficacy of intravenous sotalol for suppressing inducibility of supraventricular tachycardias at rest and during isometric exercise.
Topics: Adult; Analysis of Variance; Electrocardiography; Exercise Test; Female; Heart Conduction System; Hu | 1992 |
Mechanism of action of sotalol in supraventricular arrhythmias.
Topics: Heart Conduction System; Humans; Sotalol; Stereoisomerism; Tachycardia, Supraventricular | 1990 |
Mechanisms of termination of supraventricular tachycardias by intravenous class III antiarrhythmic agents. A comparison of amiodarone and sotalol.
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Child; Female; Heart Conduction System; Human | 1989 |
Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Female; | 1989 |
[Intravenous sotalol in the acute treatment of supraventricular tachycardias].
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Injections, Intravenous; Male; Middle Aged; Sotalol; | 1986 |
Oral sotalol in neonatal supraventricular tachycardia.
Topics: Humans; Infant, Newborn; Recurrence; Sotalol; Tachycardia, Supraventricular | 1988 |
Sotalol-induced torsades de pointes in a patient with pre-existent normal response to programmed ventricular stimulation.
Topics: Aged; Cardiac Pacing, Artificial; Electrocardiography; Female; Humans; Long QT Syndrome; Sotalol; Ta | 1987 |
Sotalol in patients with Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Adult; Cardiac Pacing, Artificial; Electrocardiography; Exercise Test; Female; | 1987 |
[QT time and the ventricular refractory period in programmed electrical stimulation of the heart in patients with ventricular and supraventricular tachycardias--effect of sotalol].
Topics: Adult; Aged; Cardiac Pacing, Artificial; Cardiomyopathy, Dilated; Electrocardiography; Female; Heart | 1986 |